The Relationship Between Irisin and Bone Health in Individuals With Spinal Cord Injury
IBSCI
The Influence of Irisin/FNDC5 on Bone Mineral Density and Fracture Risk in Individuals With Spinal Cord Injury
1 other identifier
interventional
11
1 country
1
Brief Summary
This study will examine the relationship between circulating irisin and bone health individuals with spinal cord injury. Additionally, this study seeks to examine the influence of muscle fiber type on circulating irisin and identify an exercise-based means to increase irisin concentrations.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 31, 2022
CompletedFirst Posted
Study publicly available on registry
April 8, 2022
CompletedStudy Start
First participant enrolled
May 5, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2025
CompletedJuly 11, 2025
July 1, 2025
2 years
March 31, 2022
July 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Irisin - Bone measure correlations
Circulating irisin concentrations will be correlated with DXA and HR-pQCT bone measures
Baseline; at rest
FNDC5 gene expression
FNDC5 gene expression will be measured in vastus lateralis skeletal muscle biopsies via RT-PCR to determine if potential differences in circulating irisin concentrations may be attributed to differential gene expression.
Baseline; at rest
Exercise induced change in irisin concentration
Circulating irisin concentrations will be measured before and immediately following an arm ergometer high-intensity interval exercise bout to determine if this exercise modality can increased circulating irisin concentrations in individuals with SCI and controls
baseline and immediately post-exercise
Study Arms (2)
Individuals with SCI
ACTIVE COMPARATORMale and female, Veteran and non-Veteran participants with traumatic SCI will complete the baseline blood draw, muscle biopsy and DXA/HR-pQCT bone imaging. This group will complete blood draws before and after arm ergometer high-intensity interval exercise bout.
Controls (No SCI)
ACTIVE COMPARATORMale and female Veterans, age and sex-matched to participants with SCI will complete the baseline blood draw, muscle biopsy and DXA/HR-pQCT bone imaging. This group will complete blood draws before and after arm ergometer high-intensity interval exercise bout.
Interventions
Participants with and without SCI will complete an arm ergometer, high-intensity interval exercise bout. The exercise bout will be performed at a relative intensity based on previously determined peak power output during an arm ergometer graded exercise test.
Eligibility Criteria
You may qualify if:
- Participants with SCI:
- age 18 years or older
- traumatic SCI at the cervical level 4 or lower that occurred at least 12 months prior to the start of the study
- American Spinal Injury Association Impairment Scale A, B or C
- uses a manual wheelchair as primary means of mobility (30+ hours per week)
- is able to perform a transfer independently to and from a wheelchair
- has adequate strength and upper extremity function to operate an arm ergometer
- Control Participants:
- age and sex-matched to participant with SCI
You may not qualify if:
- Participants with SCI:
- active use of medications which potentially affect bone metabolism, including: parathyroid hormone and analogs, androgenic or estrogenic steroids, bisphosphonates, oral glucocorticoids (use for more than 3 months)
- history of fractures or dislocations in the upper extremity from which the participant has not fully recovered
- upper limb pain or injury that interferes with the ability to perform aerobic exercise
- recent hospitalization for any reason (within the past three months)
- history of coronary artery disease, coronary bypass surgery or other cardiorespiratory events or conditions
- likely to experience clinically significant autonomic dysreflexia and/ or orthostatic hypotension in response to vigorous exercise
- endocrinopathy or metabolic disorders of the bone
- e.g. Paget's disease, renal bone disease
- history of allergic reaction to lidocaine
- any other conditions that the person's primary care physician deems is a contraindication to participation in arm ergometry exercise stress testing or vigorous exercise
- pregnant
- participation in another "Greater than Minimal Risk" study.
- Control Participants:
- active use of medications which potentially affect bone metabolism, including: parathyroid hormone and analogs, androgenic or estrogenic steroids, bisphosphonates, oral glucocorticoids (use for more than 3 months)
- +7 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
Pittsburgh, Pennsylvania, 15240, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Adam J. Sterczala, PhD
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- FED
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 31, 2022
First Posted
April 8, 2022
Study Start
May 5, 2023
Primary Completion
April 30, 2025
Study Completion
April 30, 2025
Last Updated
July 11, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share